Trinity Biotech
TRIB
79 hedge funds and large institutions have $191M invested in Trinity Biotech in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 30 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 79 → 79 (0)
6% less capital invested
Capital invested by funds: $203M → $191M (-$11.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
43% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 30
94% less call options, than puts
Call options by funds: $1K | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Paradice Investment Management
Denver,
Colorado
|
+$2.15M |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$1.69M |
| 3 |
Millennium Management
New York
|
+$700K |
| 4 |
PCA
Prospect Capital Advisors
Sausalito,
California
|
+$472K |
| 5 |
BCM
Breithorn Capital Management
New York
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.24M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.86M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.02M |
| 4 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
-$939K |
| 5 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
-$899K |
TRIB Hedge Fund Activity: Q2 2016 in Review
79 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2016, worth a combined $191M — down 5.6% from $203M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TRIB positions and 6 closed out — a net gain of 1 holder — while 17 added to existing stakes and 30 trimmed.
The largest buyer was Paradice Investment Management, adding an estimated $2.15M. The largest seller was Bank of Montreal, cutting an estimated $3.24M.
- 79 institutional investors held Trinity Biotech (TRIB) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $191M of Trinity Biotech stock for Q2 2016, down 5.6% quarter-over-quarter.
- 7 funds opened new Trinity Biotech positions in Q2 2016 and 6 closed out, a net change of +1 holder.
- The largest Trinity Biotech buyer in Q2 2016 was Paradice Investment Management, an estimated $2.15M added.
- The largest Trinity Biotech seller in Q2 2016 was Bank of Montreal, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2016.